Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Breast 1

Conditions

Epilepsy 3Small Cell Lung Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × LY3295668 erbumine × Clear all
NCT03092934 2021-07-02

A Study of AK-01 (LY3295668) in Solid Tumors

Eli Lilly and Company

Phase 1/2 Completed
13 enrolled 17 charts
BreastHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡